US EditionGeneric competitor to Ozempic is authorized in the United States - World Stock Market
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
It's a victory for the national industry, says EMS medical director to CNN about the production of Ozempic's competitor - World Stock Market
The National Health Surveillance Agency (Anvisa) authorized the Brazilian pharmaceutical company EMS to produce two medicines indicated for the treatment of diabetes and obesity. This approval marks a significant moment for the national pharmaceutical industry, allowing the manufacture of the first Brazilian competitor for medicines such as Ozempic. Dr. Ian Gonçalves Junior, medical director of EMS, in an interview with CNN 360° this Tuesday (…
The National Health Surveillance Agency (Anvisa) authorized the production of liraglutide-based drugs in Brazil by the pharmaceutical company EMS, marking a crucial moment for the company. This approval places the company at the forefront of the GLP-1 analog segment (Ozempic), increasing its internationalization prospects. The objective is to establish a strong presence in the Brazilian market... The post Anvisa endorses Pharmacists EMS to produ…
Anvisa (National Health Surveillance Agency) authorized this Monday (23), via Official Gazette, the production by the pharmaceutical company EMS of two liraglutide-based drugs, Lirux, indicated for the treatment of diabetes, and Olire, to combat obesity. They will begin to be marketed throughout 2025. Liraglutide is the active ingredient in the drugs Saxenda and Victoza from Novo Nordisk, whose patent fell this year here in Brazil. It is classif…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
